Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 21;4(4):CD011408.
doi: 10.1002/14651858.CD011408.pub2.

Haloperidol discontinuation for people with schizophrenia

Adib Essali  1 , Khaled Turkmani, Shaimaa Aboudamaah, Alaa AbouDamaah, Mohammad Reyad Diaa Aldeen, Mohamad Essam Marwa, Nawar AlMounayer
Affiliations

Haloperidol discontinuation for people with schizophrenia

Adib Essali et al. Cochrane Database Syst Rev. .

Abstract

Background: Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews.

Objectives: To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol.

Search methods: On 20 February 2015, 24 May 2017, and 12 January 2019, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials including trial registers.

Selection criteria: We included clinical trials randomising adults with schizophrenia or related disorders who were receiving haloperidol, and were stable. We included trials that randomised such participants to either continue their current treatment with haloperidol or discontinue their haloperidol treatment. We included trials that met our selection criteria and reported usable data.

Data collection and analysis: We independently checked all records retrieved from the search and obtained full reports of relevant records for closer inspection. We extracted data from included studies independently. All usable data were dichotomous, and we calculated relative risks (RR) and their 95% confidence intervals (95% CI) using a fixed-effect model. We assessed risk of bias within the included studies and used GRADE to create a 'Summary of findings' table.

Main results: We included five randomised controlled trials (RCTs) with 232 participants comparing haloperidol discontinuation with haloperidol continuation. Discontinuation was achieved in all five studies by replacing haloperidol with placebo. The trials' size ranged between 23 and 87 participants. The methods of randomisation, allocation concealment and blinding were poorly reported.Participants allocated to discontinuing haloperidol treatment were more likely to show no improvement in global state compared with those in the haloperidol continuation group (n = 49; 1 RCT; RR 2.06, 95% CI 1.33 to 3.20; very low quality evidence: our confidence in the effect estimate is limited due to relevant methodological shortcomings of included trials). Those who continued haloperidol treatment were less likely to experience a relapse compared to people who discontinued taking haloperidol (n = 165; 4 RCTs; RR 1.80, 95% CI 1.18 to 2.74; very low quality evidence). Satisfaction with treatment (measured as numbers leaving the study early) was similar between groups (n = 43; 1 RCT; RR 0.13, 95% CI 0.01 to 2.28; very low quality evidence).No usable mental state, general functioning, general behaviour or adverse effect data were reported by any of the trials.

Authors' conclusions: This review provides limited evidence derived from small, short-term studies. The longest study was for one year, making it difficult to generalise the results to a life-long disorder. Very low quality evidence shows that discontinuation of haloperidol is associated with an increased risk of relapse and a reduction in the risk of 'global state improvement'. However, participant satisfaction with haloperidol treatment was not different from participant satisfaction with haloperidol discontinuation as measured by leaving the studies early. Due to the very low quality of these results, firm conclusions cannot be made. In addition, the available studies did not report usable data regarding the adverse effects of haloperidol treatment.Considering that haloperidol is one of the most widely used antipsychotic drugs, it was surprising that only a small number of studies into the benefit and harm of haloperidol discontinuation were available. Moreover, the available studies did not report on outcomes that are important to clinicians and to people with schizophrenia, particularly adverse effects and social outcomes. Better designed trials are warranted.

PubMed Disclaimer

Conflict of interest statement

Adib Essali: none known

Khaled Turkmani: none known

Shaimaa Aboudamaah: none known

Alaa Aboudamaah: none known

Mohammad Reyad Diaa Aldeen: none known

Mohamad Essam Marwa: none known

Nawar Almounayer: none known

Figures

1
1
Study flow diagram (for searching up to January 2019)
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 HALOPERIDOL DISCONTINUATION versus HALOPERIDOL CONTINUATION, Outcome 1 Global state: clinically important change ‐ not improved (CGI, ) ‐ short term.
1.2
1.2. Analysis
Comparison 1 HALOPERIDOL DISCONTINUATION versus HALOPERIDOL CONTINUATION, Outcome 2 Global state: relapse.
1.3
1.3. Analysis
Comparison 1 HALOPERIDOL DISCONTINUATION versus HALOPERIDOL CONTINUATION, Outcome 3 Satisfaction with treatment: various measures ‐ long term.
1.4
1.4. Analysis
Comparison 1 HALOPERIDOL DISCONTINUATION versus HALOPERIDOL CONTINUATION, Outcome 4 Cognitive functioning: change in memory ‐ short term.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011408

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Eklund 1990 {published data only}
    1. Eklund K. Low dose of haloperidol decanoate is effective against relapses in schizophrenia patients. A double‐blind placebo controlled study. Proceedings of the 17th Collegium Internationale Neuro‐Psychopharmacologicum Congress; 1990 Sep 10‐14; Kyoto, Japan. 1990:287. [CSzG: Ref12924]
    1. Eklund K, Forsman A. Minimal effective dose and relapse ‐ double‐blind trial: haloperidol decanoate vs. placebo. Clinical Neuropharmacology 1991;14(Suppl 2):S7‐15. [CSzG: Ref747] - PubMed
Gilbertson 1997 {published data only}
    1. Gilbertson MW, Kammen DP. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia. Biological Psychiatry 1997; Vol. 42, issue 7:585‐95. [CSzG: Ref3295; MEDLINE: ] - PubMed
Nishikawa 1984 {published data only}
    1. Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom‐free schizophrenics ‐ a comparative dose‐response study of haloperidol and propericiazine. Psychopharmacology 1984;82(3):153‐6. [CSzG: Ref2168] - PubMed
Ota 1973 {published data only}
    1. Ota KY, Kurland AA. A double‐blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. Journal of Clinical Pharmacology and New Drugs 1973;13(2):99‐110. [CSzG: Ref2318] - PubMed
Ruskin 1991 {published data only}
    1. Ruskin PE, Nyman G. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo‐controlled, double‐blind trial. Journal of Nervous and Mental Disease 1991;179(4):212‐4. [CSzG: Ref2471; MEDLINE: ] - PubMed

References to studies excluded from this review

Allen 1997 {published data only}
    1. Allen DN, Gilbertson MW, Barry E, Kammen DP, Gurklis JA. Haloperidol improves memory in schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17‐22; San Diego, California, USA 1997.
Barak 2005 {published data only}
    1. Barak Y, Swartz M, Plopsky I. Assessing cardiovascular risks of olanzapine treatment: a 6‐month study versus haloperidol in schizophrenia patients. International Clinical Psychopharmacology 2005; Vol. 20, issue 6:315‐7. - PubMed
Eli 2003 {published data only}
    1. Eli Lilly Company. Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment. Eli Lilly and Company Clinical Trial Registry 2003.
    1. NCT00191555. Double‐blind long‐term study comparing the efficacy and safety of olanzapine versus haloperidol in patients with schizophrenia previously stabilized with conventional antipsychotic treatment. clinicaltrials.gov/ct2/show/NCT00191555 (accessed 10 April 2019).
Fang 2012 {published data only}
    1. Fang M, Chen H, Li LH, Wu R, Li Y, Liu L, et al. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia. International Clinical Psychopharmacology 2012; Vol. 27, issue 2:107‐13. - PubMed
Fleischhacker 1996 {published data only}
    1. Copolov DL, Link CG, Kowalcyk B. A multicentre, double blind, randomized comparison of quetiapine (ICI 204,636, 'seroquel') and haloperidol in schizophrenia. Psychological Medicine 2000; Vol. 30, issue 1:95‐105. [MEDLINE: ] - PubMed
    1. Fleischhacker WW, Linz CG, Hurst BC. ICI 204636 ('seroquel') ‐ a putative new atypical antipsychotic: results from phase III trials. Schizophrenia Research 1996; Vol. 18, issue 2‐3:132.
    1. Hellewell JS, Hurst BC, Link CG. Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('seroquel'‐ICI 204,636). European Neuropsychopharmacology 1996; Vol. 6, issue Suppl 4:123.
    1. Link C, Farrow L. "Seroquel"(tm) (ICI 204, 636) EPS and prolactin ‐ comparison with haloperidol. Proceedings of the 10th World Congress of Psychiatry; 1996 Aug 23‐28; Madrid, Spain 1996.
    1. Link C, Kowalcyzk B, Farrow L. "Seroquel"(tm) (ICI 204,636) EPS and prolactin: comparison with haloperidol. Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 Jul 7‐12; London, UK 1996.
Glazer 1990 {published data only}
    1. Glazer WM, Hafez H. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophrenia Research 1990; Vol. 3, issue 5‐6:315‐20. [MEDLINE: ] - PubMed
    1. Glazer WM, Hafez HM, Benarroche CL. Molindone and haloperidol in tardive dyskinesia. Journal of Clinical Psychiatry 1985; Vol. 46, issue 8 Pt. 2:4‐7. - PubMed
Himei 2005 {published data only}
    1. Himei A, Okamura T. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry and Clinical Neurosciences. Australia, 2005; Vol. 59, issue 5:556‐62. [MEDLINE: ] - PubMed
Lee 2014 {published data only}
    1. Lee B, Vogel S, Sisk S, Daniel A, Yao J. The Effects of Dopamine Antagonism on Reward Learning in Schizophrenia. Archives of Clinical Neuropsychology 2014;29(6):580.
NCT00044655 2002 {published data only}
    1. Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, et al. Effectiveness of switching from long‐acting injectable fluphenazine or haloperidol decanoate to long‐acting injectable risperidone microspheres: An open‐label, randomized controlled trial. Journal of Clinical Psychiatry 2012; Vol. 73, issue 5:669‐75. - PMC - PubMed
    1. NCT00044655. Effectiveness of switching antipsychotic medications. clinicaltrials.gov/ct2/show/NCT00044655 (accessed 10 April 2019).
Nordic 1986 {published data only}
    1. Gerlach J. Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale 1988; Vol. 14:227‐32. - PubMed
    1. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986; Vol. 90, issue 4:423‐9. [MEDLINE: ] - PubMed
    1. Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. The effects of neuroleptics on tardive dyskinesias. A video‐controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden [Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol + biperiden]. Ugeskrift for Laeger 1987; Vol. 149, issue 25:1682‐5. [MEDLINE: ] - PubMed
Velligan 1999 {published data only}
    1. Velligan DI, Prihoda T, Maples N, Ritch JL, Miller AL. Neurocognitive advantages of quetiapine. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5‐10; New Orleans, Louisiana, USA. 2001.
    1. Velligan DI, Pultz J, Csernansky JG, Hoff AL, Mahurin R, Miller AL, et al. Changes in cognitive function with quetiapine fumarate versus haloperidol. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999.
    1. Velligan DI, Pultz J, Newcomer JW. Changes in cognitive function with quetiapine versus haloperidol. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25‐Nov 2; New Orleans, Louisiana, USA. 1999.

References to studies awaiting assessment

Gaebel 2002 {published data only}
    1. Gaebel W, Hans‐juergen M. Treatment strategies in first episode schizophrenia. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24‐29; Yokohama, Japan. 2002.
    1. Gaebel W, Moeller HJ. Measures to prevent relapse in long‐term treatment: results from the German Research Network on Schizophrenia. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. 2006.
    1. Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer WVWM, et al. Pharmacological long‐term treatment strategies in first episode schizophrenia‐‐study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. European Archives of Psychiatry and Clinical Neuroscience. Germany, 2004; Vol. 254, issue 2:129‐40. [MEDLINE: ] - PubMed
    1. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al. Relapse prevention in first‐episode schizophrenia ‐ maintenance vs intermittent drug treatment with prodrome‐based early intervention: Results of a randomized controlled trial within the german research network on schizophrenia. Journal of Clinical Psychiatry 2011;72(2):205‐18. - PubMed
    1. Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Wilmsdorff M, et al. Rates and predictors of remission in first‐episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research 2014;152(2‐3):478‐86. - PubMed

Additional references

Adams 2013
    1. Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003082] - DOI - PMC - PubMed
Albert 1979
    1. Albert MS, Butters N, Levin J. Temporal gradients in theretrograde amnesia of patients with alcoholic Korsakoff'sdisease. Archives of Neurology 1979;36(4):211‐6. - PubMed
Almerie 2007
    1. Almerie MQ, Alkhateeb H, Essali A, Matar HE, Rezk E. Cessation of medication for people with schizophrenia already stable on chlorpromazine. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006329] - DOI - PMC - PubMed
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200. - PMC - PubMed
Baldessarini 1985
    1. Baldessarini RJ. Chemotherapy in psychiatry: principles and practice. Cambridge, MA: Harvard University Press, 1985.
Berger 2003
    1. Berger M. Mental illness. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. Urban & Fischer, 2003.
Bergman 2018
    1. Bergman H, Soares‐Weiser K. Anticholinergic medication for antipsychotic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2018, Issue 1. [DOI: 10.1002/14651858.CD000204.pub2] - DOI - PMC - PubMed
Bhattacharjee 2016
    1. Bhattacharjee J, El‐Sayeh HG. Aripiprazole versus haloperidol for people with schizophrenia and schizophrenia‐like psychoses. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD012073; CD012073] - DOI
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. - PubMed
Bunney 1963
    1. Bunney WE, Hamburg DA. Methods for reliable longitudinal observation of behavior. Archives of General Psychiatry 1963;9:280‐94. - PubMed
Carpenter 1994
    1. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330(10):681‐90. - PubMed
Davis 1975
    1. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 1975;132(12):1237‐45. - PubMed
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. The 8th International Cochrane Colloquium. Cape Town: The Cochrane Collaboration, 25‐28 Oct 2000.
Deeks 2011
    1. Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Dold 2015
    1. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD009831.pub2] - DOI - PMC - PubMed
Donnelly 2013
    1. Donnelly L, Rathbone J, Adams CE. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD001951.pub2; CD001951] - DOI - PMC - PubMed
Duggan 2005
    1. Duggan L, Fenton M, Rathbone J, Dardennes R, El‐Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] - DOI - PMC - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. - PMC - PubMed
Essali 1993
    1. Essali MA, Maddocks PD. Seventeen years in the life of a depot neuroleptic clinic ‐ an audit study of schizophrenia and other psychosis. British Journal of Medical Economics 1993;6:3‐11.
Essali 2014
    1. Essali A, Turkmani K, Aboudamaah S, AbouDamaah A, Dia'a Aldeen MR, Marwa ME, et al. Haloperidol discontinuation for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011408; CD011408] - DOI - PMC - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10. - PubMed
Gilbert 1995
    1. Gilbert P, Harris MJ, McAdams LA, Bowers MB, Charney DS, Glazer WM. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 1995;52:173‐88. - PubMed
Hanafi 2017
    1. Hanafi I, Arafat S, Al Zayed L, Sukkar M, Albeirakdar A, Krayem D, et al. Haloperidol (route of administration) for people with schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 10. [DOI: 10.1002/14651858.CD012833; CD012833] - DOI
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011a
    1. Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
    1. Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Huf 2016
    1. Huf G, Alexander J, Gandhi P, Allen MH. Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD005146.pub3; CD005146] - DOI - PMC - PubMed
Hutton 2009
    1. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. - PubMed
Irving 2006
    1. Irving CB, Adams CE, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003082.pub2] - DOI - PMC - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Khushu 2016
    1. Khushu A, Powney MJ. Haloperidol for long‐term aggression in psychosis. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2016, issue 11. [DOI: 10.1002/14651858.CD009830.pub2; CD009830] - DOI - PMC - PubMed
Kudo 1999
    1. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: An update. Clinical Pharmacokinetics 1999;37:435‐56. - PubMed
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. - PubMed
Leucht 2007
    1. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183‐91. - PMC - PubMed
Leucht 2008
    1. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WL. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2; CD004278] - DOI - PMC - PubMed
Leucht 2009
    1. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second‐generation antipsychotic drugs? A meta‐analysis of placebo‐controlled trials. Molecular Psychiatry 2009;14:429‐47. - PubMed
Leucht 2012
    1. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD008016] - DOI - PubMed
Lohse 2009
    1. Lohse MJ, Müller‐Oerlinghausen B. Psychopharmaka. In: Schwabe U, Pfaffrath D editor(s). Arzneimittelverordnungsreport. Heidelberg: Springer, 2009:767‐810.
López‐Munoz 2009
    1. López‐Munoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Research Bulletin 2009;79:130‐41. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Marvaha 2004
    1. Marvaha S, Johnson S. Schizophrenia and employment ? A review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337‐49. - PubMed
McGrath 2008
    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiology 2008;30:67‐76. - PubMed
Momcilovic 2014
    1. Momcilovic S, Dickenson R, Adams CE. Anticholinergics for neuroleptic‐induced parkinsonism and tardive dyskinesia. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011262] - DOI
Moncrieff 2015
    1. Moncrieff J. Antipsychotic Maintenance Treatment: Time to Rethink?. PLoS Med 12(8): 2015;12(8):e1001861. - PMC - PubMed
Nestor 1990
    1. Nestor PG, Faux SF, McCarley RW, Shenton ME, Sands SF. Measurement of visual sustained attention in schizophreniausing signal detection analysis and a newly developedcomputerized CPT task. Schizophrenia Research 1990;3:329‐32. - PubMed
Ostinelli 2017
    1. Ostinelli EG, Brooke‐Powney MJ, Li X, Adams CE. Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews 2017, Issue 7. [DOI: 10.1002/14651858.CD009377.pub3] - DOI - PMC - PubMed
Ostinelli 2018
    1. Ostinelli EG, Hussein M, Ahmed U, Rehman FU, Miramontes K, Adams CE. Risperidone for psychosis‐induced aggression or agitation (rapid tranquillisation). Cochrane Database of Systematic Reviews 2018, Issue 4. [DOI: 10.1002/14651858.CD009412.pub2] - DOI - PMC - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating scale. Psychological Reports 1962;10:799‐812.
Quraishi 1999
    1. Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001361; CD001361] - DOI - PMC - PubMed
Ray 2017
    1. Ray S, Ray A, Gopi A, Hunter R. Haloperidol versus risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2017, Issue 7. [DOI: 10.1002/14651858.CD012728; CD012728] - DOI
Reitan 1959
    1. Reitan RM, Tarshes EL. Differential effects of lateralized brain lesions on the Trail Making Test. Journal of Nervous and Mental Disease 1959;129:257‐62. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane.handbook.org.
Shepherd 1989
    1. Shepherd M, Watt D, Falloon I, Smeeton N. The natural history of schizophrenia: a five‐year follow‐up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine. Monograph supplement 1989;15:1‐46. - PubMed
Shokraneh 2017
    1. Shokraneh F, Adams CE. Study‐based registers of randomized controlled trials: Starting a systematic review with data extraction or meta‐analysis. BioImpacts 2017;7(4):209‐17. [DOI: 10.15171/bi.2017.25] - DOI - PMC - PubMed
Srisurapanont 2004
    1. Srisurapanont M, Maneeton B, Maneeton N, Lankappa S, Gandhi R. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000967.pub2] - DOI - PMC - PubMed
Sterne 2011
    1. Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Suttajit 2013
    1. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD007815.pub2] - DOI - PMC - PubMed
Tardy 2014
    1. Tardy M, Huhn M, Engel RR, Leucht S. Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD009369.pub2] - DOI - PMC - PubMed
Tsuang 1978
    1. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35(2):153‐5. - PubMed
Wechsler 1987
    1. Wechsler D. WMS‐R: Wechsler Memory Scale–Revised: Manual. Harcourt Brace Jovanovich, San Antonio: The Psychological Corporation, 1987.
Xia 2009
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Xiberas 2001
    1. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'H C, Maziere B, et al. Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 2001;179:503‐8. - PubMed

Publication types

MeSH terms